ClinicalTrials.gg
CompletedNCT00348283Updated Apr 11, 2011Results posted

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

A Phase 3 interventional study of adalimumab and placebo in Crohn's Disease, sponsored by Abbott. Completed at 21 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-11.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
23rd of 42
135 · median 143
Started
2006
with 2 others
Phase 3
22 of 42
none open now
Registered
7th of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 23rd largest by enrollment, is one of 3 that started in 2006, is one of 22 in phase 3, and was the 7th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The goal of this study was to test whether adalimumab can induce mucosal healing in subjects with moderate to severe ileocolonic Crohn's Disease.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Crohn's Disease for greater than 4 months.
  • A diagnosis of ileocolonic Crohn's Disease confirmed by endoscopy or radiologic evaluation within 3 years of Baseline.
  • For subjects who have had operations in the ileocolonic region of the intestine after documented diagnosis of ileocolonic disease, postoperative recurrence of the disease must be documented.
  • Endoscopic documentation of ulceration at Screening corresponding to a score of 2 or 3 in at least one of the five segments of the colon on the Ulcerated Surface subscore of the Simple Endoscopic Score for Crohn's Disease (SES-CD).
  • Crohn's Disease Activity Index (CDAI) score of >= 220 and \<= 450.
  • Males and females >= 18 and \<= 75 years of age at the Baseline visit.
  • Adequate cardiac, renal and hepatic function as determined by the Principal Investigator and demonstrated by Screening laboratory evaluations, questionnaires, and physical examination results that do not indicate an abnormal clinical condition which would place the subject at undue risk and thus preclude subject participation in the study.
  • Subjects must be able to self-inject study medication or have a designee or healthcare professional who can inject the study medication.
  • Subjects must agree to undergo up to 4 endoscopies.

Exclusion criteria

Exclusion Criteria:

  • History of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma - in-situ of the cervix.
  • History of listeria, (HIV), , an immunodeficiency syndrome, central nervous system (CNS) demyelinating disease, or untreated tuberculosis (TB).
  • Subject with a current diagnosis of ulcerative colitis or indeterminate colitis as determined by the Investigator and Abbott Medical Monitor.
  • Subject who has had surgical bowel resections within the past 6 months or is planning any resection at any time point while enrolled in the study.
  • Subject with an ostomy or ileoanal pouch. (Subjects with a previous ileo-rectal anastomosis are not excluded).
  • Subject who has received any biological agent in the past 3 months or 5 half-lives prior to Baseline (whichever is longer).
  • Subjects with a poorly controlled medical condition and any other condition which, in the opinion of the Investigator or the sponsor, would put the subject at risk by participation in the protocol.
  • Subject who has previously used infliximab or any anti-TNF (anti tumor necrosis factor), even investigational, within 8 weeks of Baseline.
  • Subject who has previously used infliximab or any anti-TNF agent and has not clinically responded.
  • Previous treatment with adalimumab or previous participation in an adalimumab clinical study.
  • Subjects on prednisone > 40 mg/day (or equivalent).
  • Subjects on budesonide > 9 mg/day.
  • Subjects with any prior exposure to Tysabri® (natalizumab).
  • Subjects with a previous history of dysplasia of the gastrointestinal tract, or found to have dysplasia in any performed during the Screening endoscopy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Placebo comparator
    Double Blind

    Blinded study through Week 52. Adalimumab compared to placebo during blinded portion.

    Biological: adalimumab · Biological: placebo

  • Other
    Open Label

    Note: No comparator was used in Open-Label portion of study. From Week 8, subjects could have switched to open-label (OL) adalimumab 40mg administered subcutaneously (SC) every other week (eow)or OL adalimumab 40 mg SC every week (ew) dosing to treat disease flare or non-response. At Week 52, all remaining subjects were allowed to switch to the Open-Label portion of the study.

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.

    Also known as: ABT-D2E7, Humira

  • Biologicalplacebo

    At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.

  • Biologicaladalimumab

    At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Number of Subjects Without Mucosal Ulceration at Week 12

    Subjects were to have undergone up to 4 endoscopies to evaluate the presence or absence of mucosal ulceration: at Screening, at Week 12 (subjects who moved to open label (OL) drug between Week 8 and Week 12 because of disease flare or non-response were evaluated by endoscopy prior to receiving OL dosing), at the time of switch from blinded study drug to OL adalimumab at any time after Week 12, and at Week 52 or Early Termination. Subjects who remained blinded for the entire 52-week trial or switched to OL adalimumab between Week 8 and Week 12 were to have undergone 3 endoscopies.

    Time frame: Week 12

Secondary outcomes

  1. Number of Subjects With Clinical Remission Crohn's Disease Activity Index (CDAI) < 150 at Week 12

    Clinical remission is defined as a CDAI less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.

    Time frame: Week 12

  2. Number of Subjects Without Mucosal Ulceration at Week 52

    The number of subjects receiving blinded study drug in each treatment group who were without mucosal ulceration at Week 52.

    Time frame: Week 52

  3. Number of Subjects With Clinical Remission (CDAI < 150) at Week 52

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.

    Time frame: Week 52

  4. Number of Subjects Without Mucosal Ulceration at Both Week 12 and Week 52

    The number of subjects receiving blinded study drug in each treatment group who were without mucosal ulceration at both Week 12 and Week 52.

    Time frame: Weeks 12 and 52

  5. Number of Subjects With Clinical Remission (CDAI < 150) at Both Week 12 and Week 52

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.

    Time frame: Weeks 12 and 52

07

Results

Posted Feb 11, 2010

Participant flow

Subjects were to be enrolled in 9 countries. Subjects were enrolled at 19 sites in 8 countries. No subjects were enrolled in Sweden.

Induction
Participant flow — Induction
MilestonePlaceboAdalimumab
Started0135
Completed0129
Not completed06
Withdrew: Adverse event02
Withdrew: Protocol violation04
Double Blind
Participant flow — Double Blind
MilestonePlaceboAdalimumab
Started6564
Completed6054
Not completed510
Withdrew: Adverse event25
Withdrew: Withdrawal by subject11
Withdrew: Protocol violation01
Withdrew: Lack of efficacy22
Withdrew: Pregnancy01
Open Label
Participant flow — Open Label
MilestonePlaceboAdalimumab
Started0100
Completed066
Not completed034
Withdrew: Adverse event08
Withdrew: Withdrawal by subject04
Withdrew: Lost to follow-up01
Withdrew: Lack of efficacy013
Withdrew: Administrative reasons05
Withdrew: Subject moved to the united states01
Withdrew: Pregnancy01
Withdrew: Sponsor decision01

Outcome measures

PrimaryNumber of Subjects Without Mucosal Ulceration at Week 12

Subjects were to have undergone up to 4 endoscopies to evaluate the presence or absence of mucosal ulceration: at Screening, at Week 12 (subjects who moved to open label (OL) drug between Week 8 and Week 12 because of disease flare or non-response were evaluated by endoscopy prior to receiving OL dosing), at the time of switch from blinded study drug to OL adalimumab at any time after Week 12, and at Week 52 or Early Termination. Subjects who remained blinded for the entire 52-week trial or switched to OL adalimumab between Week 8 and Week 12 were to have undergone 3 endoscopies.

Time frame:
Week 12
Reported as:
Number · Subjects
Number of Subjects Without Mucosal Ulceration at Week 12
SubjectsPlaceboAdalimumab
Number of Subjects Without Mucosal Ulceration at Week 12817
Statistical analysis
  • Placebo vs Adalimumab · Cochran-Mantel-Haenszel · p = 0.056 (The P value is from Cochran-Mantel-Haenszel test with clinical response (CR-70 responder status) at Week 4 as the stratification factor.)Because of the hierarchical testing scheme used for testing the ranked secondary endpoints, alpha level of 0.05 was used at each stage of testing.
SecondaryNumber of Subjects With Clinical Remission Crohn's Disease Activity Index (CDAI) < 150 at Week 12

Clinical remission is defined as a CDAI less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.

Time frame:
Week 12
Reported as:
Number · Subjects
Number of Subjects With Clinical Remission Crohn's Disease Activity Index (CDAI) < 150 at Week 12
SubjectsPlaceboAdalimumab
Number of Subjects With Clinical Remission Crohn's Disease Activity Index (CDAI) < 150 at Week 121830
Statistical analysis
  • Placebo vs Adalimumab · Cochran-Mantel-Haenszel · p = 0.021 (The P value is from Cochran-Mantel-Haenszel test with clinical response (CR-70 responder status) at Week 4 as the stratification factor.)
SecondaryNumber of Subjects Without Mucosal Ulceration at Week 52

The number of subjects receiving blinded study drug in each treatment group who were without mucosal ulceration at Week 52.

Time frame:
Week 52
Reported as:
Number · Subjects
Number of Subjects Without Mucosal Ulceration at Week 52
SubjectsPlaceboAdalimumab
Number of Subjects Without Mucosal Ulceration at Week 52015
Statistical analysis
  • Placebo vs Adalimumab · Cochran-Mantel-Haenszel · p = <0.001 (The P value is from Cochran-Mantel-Haenszel test with clinical response (CR-70 responder status) at Week 4 as the stratification factor.)
SecondaryNumber of Subjects With Clinical Remission (CDAI < 150) at Week 52

Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.

Time frame:
Week 52
Reported as:
Number · Subjects
Number of Subjects With Clinical Remission (CDAI < 150) at Week 52
SubjectsPlaceboAdalimumab
Number of Subjects With Clinical Remission (CDAI < 150) at Week 52621
Statistical analysis
  • Placebo vs Adalimumab · Cochran-Mantel-Haenszel · p = 0.001 (The P value is from Cochran-Mantel-Haenszel test with clinical response (CR-70 responder status) at Week 4 as the stratification factor.)
SecondaryNumber of Subjects Without Mucosal Ulceration at Both Week 12 and Week 52

The number of subjects receiving blinded study drug in each treatment group who were without mucosal ulceration at both Week 12 and Week 52.

Time frame:
Weeks 12 and 52
Reported as:
Number · Subjects
Number of Subjects Without Mucosal Ulceration at Both Week 12 and Week 52
SubjectsPlaceboAdalimumab
Number of Subjects Without Mucosal Ulceration at Both Week 12 and Week 5207
Statistical analysis
  • Placebo vs Adalimumab · Cochran-Mantel-Haenszel · p = 0.150 (The P value is from Cochran-Mantel-Haenszel test with clinical response (CR-70 responder status) at Week 4 as the stratification factor.)
SecondaryNumber of Subjects With Clinical Remission (CDAI < 150) at Both Week 12 and Week 52

Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) less than 150. A lower score correlates with less severe Crohn's disease activity. The CDAI range for this study was 0 to 961.

Time frame:
Weeks 12 and 52
Reported as:
Number · Subjects
Number of Subjects With Clinical Remission (CDAI < 150) at Both Week 12 and Week 52
SubjectsPlaceboAdalimumab
Number of Subjects With Clinical Remission (CDAI < 150) at Both Week 12 and Week 52319
Statistical analysis
  • Placebo vs Adalimumab · Cochran-Mantel-Haenszel · p = <0.001 (The P value is from Cochran-Mantel-Haenszel test with clinical response (CR-70 responder status) at Week 4 as the stratification factor.)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo——43/65 (66.2%)
Adalimumab—20/135 (14.8%)49/64 (76.6%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboAdalimumab
Crohn's diseaseGastrointestinal disorders—8/135
Coronary artery diseaseCardiac disorders—1/135
Ileal stenosisGastrointestinal disorders—1/135
Intestinal fistulaGastrointestinal disorders—1/135
Type IV hypersensitivity reactionImmune system disorders—1/135
Anal abscessInfections and infestations—1/135
Herpes zosterInfections and infestations—1/135
Perianal abscessInfections and infestations—1/135
TonsillitisInfections and infestations—1/135
Vulval abscessInfections and infestations—1/135
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboAdalimumab
Crohn's diseaseGastrointestinal disorders19/6515/64
NasopharyngitisInfections and infestations8/659/64
HeadacheNervous system disorders6/659/64
Abdominal painGastrointestinal disorders6/658/64
FatigueGeneral disorders2/657/64
ArthralgiaMusculoskeletal and connective tissue disorders4/657/64
Influenza like illnessGeneral disorders3/656/64
FlatulenceGastrointestinal disorders1/655/64
NauseaGastrointestinal disorders3/655/64
Upper respiratory tract infectionInfections and infestations3/655/64

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboAdalimumab 40 mg Every Other WeekTotal
<=18 years112
Between 18 and 65 years6362125
>=65 years112
Age Continuous
Age Continuous(years)PlaceboAdalimumab 40 mg Every Other WeekTotal
Mean37.2 ± 12.6037.1 ± 11.1037.1 ± 11.84
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAdalimumab 40 mg Every Other WeekTotal
Female414081
Male242448
Region of Enrollment
Region of Enrollment(participants)PlaceboAdalimumab 40 mg Every Other WeekTotal
France336
United States201232
Canada221840
Belgium142539
Austria202
Netherlands123
Germany112
Italy235
08

Study locations

21 sites
  • Atlanta, Georgia 30342, United States
  • Chicago, Illinois 60637, United States
  • Chevy Chase, Maryland 20815, United States
  • Plymouth, Minnesota 55446, United States
  • Rochester, Minnesota 55905-0002, United States
  • Mexico, Missouri 65265-3726, United States
  • Great Neck, New York 11021, United States
  • Wien, A - 1090, Austria
  • Bonheiden, 2820, Belgium
  • Leuven, B 3000, Belgium
  • Roeselare, 8800, Belgium
  • Calgary, Alberta T2N 4N1, Canada
  • Vancouver, British Columbia V6Z 2K5, Canada
  • Halifax, Nova Scotia B3H 1V7, Canada
  • Toronto, Ontario M3N 2V7, Canada
  • Lille Cedex, 59 037, France
  • Berlin, 12200, Germany
  • Hamburg, 22559, Germany
  • Kiel, 24105, Germany
  • Torino, 10128, Italy
  • Amsterdam, 1105 AZ, Netherlands
09

References and documents

Publications

  • Sandborn WJ, Lewis JD, Panes J, Loftus EV, D'Haens G, Yu Z, Huang B, Lacerda AP, Pangan AL, Feagan BG. Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease. J Crohns Colitis. 2022 Mar 14;16(3):444-451. doi: 10.1093/ecco-jcc/jjab161. PubMed 34546360 ↗
  • Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6. PubMed 29380251 ↗
  • Rutgeerts P, Reinisch W, Colombel JF, Sandborn WJ, D'Haens G, Petersson J, Zhou Q, Iezzi A, Thakkar RB. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointest Endosc. 2016 Jan;83(1):188-97.e1-3. doi: 10.1016/j.gie.2015.06.018. Epub 2015 Jul 30. PubMed 26234693 ↗
  • Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar;12(3):414-22.e5. doi: 10.1016/j.cgh.2013.06.019. Epub 2013 Jul 12. PubMed 23856361 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2006
First posted
Jul 4, 2006
Start
Aug 2006
Primary completionActual
Sep 2008
Results first posted
Feb 11, 2010
Last update
Apr 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00348283
Lead sponsor
Abbott
First posted
Jul 4, 2006
Start date
Aug 2006
Primary completion
Sep 2008
Results posted
Feb 11, 2010
Last update
Apr 11, 2011

Study contacts

Anne Andrée Camez
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion